Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases

Current Pharmaceutical Design

Volumn 19, Issue 32, 2013, Pages 5695-5703

  Fiorentino, Teresa Vanessa ^a   Prioletta, Annamaria ^b   Zuo, Pengou ^a   Folli, Franco ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Diabetes Unit   (Italy)

Author keywords

Cardiovascular disease; Diabetes mellitus; Endoplasmic reticulum stress; Hyperglycemia; Mitochondrial dysfunction; Oxidative stress

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACTIN; ACTIVATING TRANSCRIPTION FACTOR 6; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ASCORBIC ACID; CREATINE KINASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FRUCTOSE 6 PHOSPHATE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCERALDEHYDE 3 PHOSPHATE; HEXOSAMINE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOCTIC ACID; TRANSCRIPTION FACTOR; UNCOUPLING PROTEIN 1; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CELL MIGRATION; CELL PROLIFERATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISULFIDE BOND; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; GENE EXPRESSION; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; INTRACELLULAR SIGNALING; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UNFOLDED PROTEIN RESPONSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84876273640     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319320005     Document Type: Article

References (126)

1. Kannel WB, McGee DL. Diabetes and cardiovascular diseases: the Framingham Study. JAMA 1979; 241: 2035-8.
2. Stratton IM, Adler AI, Neil HA, et al. UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000; 321: 405-12.
3. Diabetes Control and Complications Trial Research Group. The relationship of a glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-83.
4. Klein R. Hyperglycemia and microvascular disease in diabetes. Diabetes Care 1995; 18: 258-68.
5. Zoungas S, Chalmers J, Ninomiya T, et al. ADVANCE Collaborative Group. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycemic thresholds. Diabetologia 2012; 55: 636-43.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
7. Seok Man Son. Reactive Oxygen and Nitrogen Species in Pathogenesis of Vascular Complications of Diabetes. Diabetes Metab J 2012; 36: 190-198.
8. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17: 24-38.
9. Chang KC, Chung SY, Chong WS, et al. Possible superoxide radical-induced alteration of vascular reactivity in aortas from streptozotocin-treated rats. J Pharmacol Exp Ther 1993; 266: 992-1000.
10. Pieper GM, Langenstroer P, Siebeneich W. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res 1997; 34: 145-56.
11. Yu HY, Inoguchi T, Kakimoto M, et al. Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase C activity in cultured aortic smooth muscle cells. Diabetologia 2001; 44: 614-20.
12. Robin P, Boulven I, Desmyter C, Harbon S, Leiber D. ET-I stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells. Am J Physiol Cell Physiol 2002; 283: C251-60.
13. Malhotra A, Kang BP, Cheung S, Opawumi D, Meggs LG. Angiotensin promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 2001; 50: 1918-26.
14. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. Clin Invest 1997; 100: 115-26.
15. Liu Y, Lei S, Gao X, et al. PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Clinical Science 2012; 122: 161-73.
16. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappa B in vascular smooth muscle cells. Diabetes 1999; 48(4): 855-64.
17. Abiko T, Abiko A, Clermont AC, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003; 52: 829-37.
18. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C: dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-45.
19. Maeno Y, Li Q, Park K, et al. Inhibition of insulin signaling in endothelial cells by protein kinase C-induced phosphorylation of p85 subunit of phosphatidylinositol 3-kinase (PI3K). J Biol Chem 2012; 287: 4518-30.
20. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-31.
21. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 1992; 89: 12043-7.
22. Yamagishi Si, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chern 1997; 272: 8723-30.
23. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes associated sustained activation of the transcription factor nuclear factorkappaB. Diabetes 2001; 50: 2792-808.
24. Bucala R, Tracey Kl, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
25. Akimoto Y, Kreppel LK, Hirano H, Hart GW. Hyperglycemia and the O-GlcNAc transferase in rat aortic smooth muscle cells: elevated expression and altered patterns of O-GlcNAcylation. Arch Biochem Biophys 2001; 389: 166-75.
26. Federici M, Menghini R, Mauriello A, et al. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by Olinked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002; 106: 466-72.
27. Love DC, Hanover JA. The hexosamine signaling pathway: deciphering the "O-GlcNAc code". Sci STKE 2005; 2005: re13.
28. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 2002; 160: 115-22.
29. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 1998; 101: 160-9.
30. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp l glycosylation. Proc Natl Acad Sci USA 2000; 97: 12222-6.
31. Rajapakse AG, Ming XF, Carvas JM, Yang Z. The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am J Physiol Heart Circ Physiol 2009; 296: H815-22.
32. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
33. Anabela P. Rolo, Carlos M. Palmeira. Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology 2006; 212(2): 167-78.
34. Trumpower BL. The protonmotive Q cycle: energy transduction by coupling of proton translocation to electron transfer by the cytochrome bc1 complex. J Biol Chem 1990; 265: 11409-12.
35. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-57.
36. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59: 249-55.
37. Giacco F, Brownlee M. Oxidative Stress and Diabetic Complications. Circ Res 2010; 107: 1058-70.
38. Folli F, Guzzi V, Perego L, et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. PLoS One 2010; 5(3): e9923.
39. Fiorina P, Folli F, Maffi P, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidneypancreas and kidney-alone transplantation. Transplantation 2003; 75: 1296-301.
40. Shah AM, Channon KM. Free radicals and redox signaling in cardiovascular disease. Heart 2004; 90: 486-7.
41. Sciacqua A, Grillo N, Quero M, Sesti G, Perticone F. Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients. Int J Mol Sci 2012; 13: 13804-15.
42. Del Turco S, Gaggini M, Daniele G, et al. Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk. Curr Pharm Des 2012; [Epub ahead of print].
43. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012; 2012: 918267.
44. Ceolotto G, Bevilacqua M, Papparella I, et al. Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase dependent mechanism in human skin fibroblasts ex vivo. Diabetes 2004; 53: 1344-51.
45. Pitocco D, Zaccardi F, Di Stasio E, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud 2010; 7: 15-25.
46. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988; 82: 735-8.
47. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-5.
48. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin dependent diabetes mellitus. J Am Coll Cardiol 1998; 31: 552-7.
49. Lonn E, Yusuf S, Hoogwerf B, et al. HOPE Study; MICRO-HOPE Study. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002; 25: 1919-27.
50. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes 2001; 50: 851-60.
51. Fukumoto H, Naito Z, Asano G, Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb 1998; 5: 29-35.
52. Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y, Miyazaki H. ROS and PDGF-beta receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 2009; 297: C389-96.
53. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-57.
54. Thandavarayan RA, Watanabe K, Ma M, et al. 14-3-3 protein regulates Ask 1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol 2008; 75: 1797-806.
55. Kelm M, Schäfer S, Dahmann R, et al. Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generation. Cardiovasc Res 1997; 36: 185-94.
56. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104: 174-80.
57. Corradi D, Callegari S, Maestri R, et al. Heme oxygenase-1 expression in the left atrial myocardium of patients with chronic atrial fibrillation related to mitral valve disease: its regional relationship with structural remodeling. Hum Pathol 2008; 39: 1162-71.
58. Guazzi M, Belletti S, Bianco E, Lenatti L, Guazzi MD. Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: different results with cardioversion. Am J Physiol Heart Circ Physiol 2006; 291: H921-8.
59. Selvaraju V, Joshi M, Suresh S, Sanchez JA, Maulik N, Maulik G. Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease--an overview. Toxicol Mech Methods 2012; 22: 330-5.
60. Helenius A. How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Mol Biol Cell 1994; 5: 253-65.
61. Lai E, Teodoro T, Volchuk A. Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology (Bethesda) 2007; 22: 193-201.
62. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ 2006; 13: 374-84.
63. Sage AT, Walter LA, Shi Y, et al. Hexosamine biosynthesis pathway flux promotes endoplasmic reticulum stress, lipid accumulation, and inflammatory gene expression in hepatic cells. Am J Physiol Endocrinol Metab 2010; 298: E499-511.
64. Zhang K. Integration of ER stress, oxidative stress and the inflammatory response in health and disease. Int J Clin Exp Med 2010; 3: 33-40.
65. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nature Cell Biology 2011; 13: 184-190.
66. Werstuck GH, Khan MI, Femia G, et al. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes 2006; 55: 93-101.
67. Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107: 1263-73.
68. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61.
69. Cunha DA, Hekerman P, Ladrière L, et al. Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. J Cell Sci 2008; 121: 2308-18.
70. Hotamisligil GS. Endoplasmic reticulum stress and atherosclerosis. Nat Med 2010; 16: 396-399.
71. Zhou J, Lhoták S, Hilditch BA, Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 2005; 111: 1814-21.
72. Colgan SM, Tang D, Werstuck GH, Austin RC. Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int J Biochem Cell Biol 2007; 39: 1843-51.
73. Jiang HY, Wek SA, McGrath BC, et al. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 2003; 23: 5651-63.
74. Andreozzi F, Laratta E, Procopio C, et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 2007; 27: 2372-83.
75. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: Cell life and death decisions. J Clin Invest 2005; 115: 2656-64.
76. Raciti GA, Iadicicco C, Ulianich L, et al. Glucosamine-induced endoplasmic reticulum stress affects glut4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia 2010; 53: 955-65.
77. Fonseca SG, Burcin M, Gromada J, Urano F. Endoplasmic reticulum stress in beta-cells and development of diabetes. Curr Opin Pharmacol 2009; 9: 763-70.
78. Beriault DR, Sharma S, Shi Y, Khan MI, Werstuck GH. Glucosamine-supplementation promotes endoplasmic reticulum stress, hepatic steatosis and accelerated atherogenesis in apoE-/-mice. Atherosclerosis 2011; 219: 134-40.
79. Civelek M, Manduchi E, Riley RJ, Stoeckert CJ Jr, Davies PF. Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ Res 2009; 105: 453-61.
80. Beriault DR, Werstuck GH. The role of glucosamine-induced ER stress in diabetic atherogenesis. Exp Diabetes Res 2012; 2012: 187018.
81. Chen Y, Liu CP, Xu KF, et al. Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced glycation end products in cultured mouse podocytes. Am J Nephrol 2008; 28: 1014-22.
82. Srinivasan V, Tatu U, Mohan V, Balasubramanyam M. Molecular convergence of hexosamine biosynthetic pathway and ER stress leading to insulin resistance in L6 skeletal muscle cells. Mol Cell Biochem 2009; 328: 217-24.
83. van der Vlies D, Makkinje M, Jansens A, et al. Oxidation of ER resident proteins upon oxidative stress: effects of altering cellular redox/antioxidant status and implications for protein maturation. Antioxid Redox Signal 2003; 5: 381-7.
84. Chakravarthi S, Bulleid NJ. Glutathione is required to regulate the formation of native disulfide bonds within proteins entering the secretory pathway. J Biol Chem 2004; 279: 39872-79.
85. Tu BP, Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol 2004; 164: 341-6.
86. Gorlach A, Klappa P, and Kietzmann T. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal 2006; 8: 1391-418.
87. Bhandary B, Marahatta A, Kim HR, Chae HJ. An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int J Mol Sci 2012; 14: 434-56.
88. Malhotra JD, Kaufman RJ. Endoplasmic Reticulum Stress and Oxidative Stress: A Vicious Cycle or a Double-Edged Sword? Antioxid Redox Signal 2007; 9: 2277-93.
89. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 2002; 277: 44784-90.
90. Nathan DM, Lachin J, Cleary P, et al. Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-303.
91. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
92. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.
93. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7.
94. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes. Diabetologia 2001; 44: 2107-14.
95. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003; 290: 486-94
96. Ceriello A, Quagliaro L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439-43.
97. Ceriello A, Bortolotti N, Motz E, et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 1998; 21: 1529-33.
98. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002; 39: 1145-50.
99. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002; 25: 737-41.
100. Monnier L, Mas E, Ginet C, et al. Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes. JAMA 2006; 295: 1681-7.
101. Seaquist ER, Miller ME, Bonds DE, et al. ACCORD Investigators. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012; 35: 409-14.
102. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-46.
103. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
104. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-72.
105. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
106. Standl E, Schnell O. Alpha-glucosidase inhibitors 2012-cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012; 9: 163-9.
107. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005; 48: 1919-24.
108. Kataoka Y, Yasuda S, Miyamoto Y, et al. DIANA study investigators. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J 2012; 76: 712-20.
109. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. [No authors listed] Lancet 1998; 352: 837-53.
110. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011; 108: 33B-41B.
111. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in nondiabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-59.
112. Cameron NE, Cotter MA. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 1999; 45: 137-46.
113. Neri S, Signorelli SS, Torrisi B, et al. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls. Clin Ther 2005; 27: 1764-73.
114. Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005; 28: 2458-64.
115. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
116. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
117. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients: A Meta-Analysis. Drugs 2012; 72(18): 2365-73.
118. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109: II34-41.
119. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61: 186-94.
120. Deo SH, Fisher JP, Vianna LC, et al. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol 2012; 303: H377-85.
121. Pignatelli P, Carnevale R, Pastori D, et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 2012; 126: 92-103.
122. Fiordaliso F, Cuccovillo I, Bianchi R, et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 2006; 79: 121-9.
123. Munzel T, Keaney JF, lr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001; 104: 1571-4.
124. Andreadou I, Farmakis D, Prokovas E, et al. Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc Res 2012; 94: 501-9.
125. Piechota-Polanczyk A, Goraca A, Demyanets S, et al. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF-κB. Eur J Vasc Endovasc Surg 2012; 44: 133-7.
126. Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep 2012; 14: 79-88.